Precision medicine

Natera, Inc. announced the publication of over 300 peer-reviewed papers featuring its cell-free DNA testing technology. These publications, appearing in prominent journals, highlight breakthroughs in early disease detection and clinical decision-making across oncology, women’s health, and organ health. Key areas include Signatera’s utility in cancer management, advancements in non-invasive prenatal testing, and improved outcomes in transplant medicine. This milestone underscores Natera’s commitment to scientific validation and enhancing clinical care.

IDEAYA Biosciences announced stock option grants to a new employee. The company awarded 95,600 shares at $22.29 per share under its 2023 plan, aiming to attract talent. Options vest over four years, with 25% vesting after the first year. IDEAYA, a precision medicine oncology company, focuses on targeted therapies based on molecular diagnostics and synthetic lethality approaches.

RetinalGenix Technologies Inc. has appointed Dr. Taimour Langaee as a scientific advisor to advance its precision medicine initiatives. Dr. Langaee, an expert in pharmacogenomics, will lead efforts on the company’s DNA GPS Pharmacogenetics platform. This platform aims to personalize treatment pathways for retinal and systemic diseases by analyzing genetic data and linking eye diseases to genetic variations, furthering RetinalGenix’s commitment to early disease detection through advanced retinal imaging.

Tempus AI launched its Fuses program to create an AI-powered diagnostic platform for precision medicine. Leveraging its vast, multimodal dataset, the initiative will build models to improve diagnostics, prognostics, and predictions. Fuses aims to translate data insights into clinically validated tests for personalized patient care, including identifying those unlikely to respond to current therapies. The program seeks to transform diagnostics and help match patients with the most effective treatments.